Mechanisms of immune-related adverse events associated with immune checkpoint blockade: using germline genetics to develop a personalized approach

Genome Med. 2019 Jun 20;11(1):39. doi: 10.1186/s13073-019-0652-8.

Abstract

Personalized care of cancer patients undergoing treatment with immune checkpoint inhibitors will require approaches that can predict their susceptibility to immune-related adverse events. Understanding the role of germline genetic factors in determining individual responses to immunotherapy will deepen our understanding of immune toxicity and, importantly, it may lead to tools for identifying patients who are at risk.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Animals
  • Antineoplastic Agents, Immunological / adverse effects*
  • Antineoplastic Agents, Immunological / therapeutic use
  • Genetic Testing / methods*
  • Genome-Wide Association Study / methods*
  • Humans
  • Neoplasms / drug therapy*
  • Neoplasms / genetics
  • Neoplasms / immunology
  • Precision Medicine / methods*
  • Receptors, Immunologic / antagonists & inhibitors*
  • Receptors, Immunologic / genetics

Substances

  • Antineoplastic Agents, Immunological
  • Receptors, Immunologic